Key result
Apixaban demonstrates clinical efficacy and safety comparable to dalteparin for the treatment of cancer-associated venous thromboembolism, with a convenient oral dosing regimen and no increased risk of major bleeding.
Why the study?
Cancer-associated venous thromboembolism presents treatment challenges due to bleeding risks, a limited list of recommended drugs, and low compliance with standard dalteparin.
Does apixaban reduce recurrent venous thromboembolism without increasing bleeding in patients with cancer-associated venous thromboembolic complications compared to dalteparin?
Does apixaban reduce recurrent venous thromboembolism without increasing bleeding in patients with cancer-associated venous thromboembolic complications compared to dalteparin?
Apixaban provides an effective and safe oral alternative to dalteparin for treating cancer-associated venous thromboembolism, with comparable bleeding risks.
Answers are grounded in this paper and cite their sources.
Apixaban may offer a convenient oral alternative for cancer-associated VTE; leaves open confirmation in prospective trials.
Cancer-associated venous thromboembolic complications are one of the main topical problems in the system of practical healthcare. Having overlapping pathogenetic mechanisms of development, thromboembolic complications accompany the oncological process and often act as its manifesting sign. Treatment of onco-associated venous thromboembolic complications is not an easy task, which is determined by the multiplicity of the pathogenetic mechanisms of hemostatic system disorders in the cohort of patients under consideration, who are threatened both in terms of the development of total PE and fatal bleeding. In addition to the features of the treatment phases, their duration, an important point in the treatment of cancer-associated thrombosis is a limited list of recommended drugs, as well as the permitted dosage regimens. The article analyzes the results of research aimed at studying the effectiveness of apixaban in the treatment of cancer-associated thromboembolic complications. Now the gold standard for the treatment of venous thromboembolic complications is dalteparin. However, low compliance in the use of dalteparin leads to premature termination of treatment or the patient's independent transition to alternative drugs. The appearance of direct oral anticoagulants has significantly changed the treatment paradigm in this morbid group of patients, while leaving a number of unresolved issues.
No takes yet. Share an insight, caveat, or question.
Fedotov et al. (2022) conducted a review in Cancer-associated venous thromboembolic complications. Apixaban vs. Dalteparin was evaluated. Apixaban demonstrates clinical efficacy and safety comparable to dalteparin for the treatment of cancer-associated venous thromboembolism, with a convenient oral dosing regimen and no increased risk of major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: